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On May 6, 1953, John H. Gibbon, 
Jr., MD – the third Samuel D. Gross 
Professor and Chair of the Department 
of Surgery (1946–1967) and Director 
of Experimental Surgery at Jefferson – 
performed the first successful surgery 
with the groundbreaking heart-lung 
machine he developed. With this 
operation, Dr. Gibbon launched a new 
era in cardiac surgery. 
As we commemorate the 60th 
anniversary of Dr. Gibbon’s 
milestone, patients of the Division of 
Cardiothoracic Surgery continue to 
benefit from Jefferson’s commitment 
to continual innovation under the 
leadership of James Diehl, MD, FACS, 
and two highly specialized programs.
State-of-the-art life support
The Adult Extracorporeal Membrane 
Oxygenation (ECMO) Program boasts 
survival rates that far exceed reported 
national rates. Established in 2010 by 
Nicholas Cavarocchi, MD, FACS, FCCP, 
Director of the Cardiac and Vascular 
Intensive Care Unit, the program’s 
leading-edge equipment provides both 
cardiac and respiratory support (oxygen) 
to individuals with severely diseased or 
damaged heart and lungs. 
At present, Jefferson is the only hospital 
in the area to utilize two transport 
devices – the SERVO-i ventilator and 
the CARDIOHELP (portable) ECMO 
machine. Using these devices, the 
Jefferson ECMO team (comprised of 
physicians and mid-level providers in 
the Cardiac ICU, JeffSTAT medical 
transportation staff, and respiratory 
therapists) is able to transport critically 
ill patients and place patients on  
ECMO before they are transferred to 
Jefferson. By placing patients on ECMO 
earlier than usual, we improve their 
chances of being successfully weaned 
from ECMO or having surgery with 
fewer complications.
60 Years of Cardiothoracic Surgery at Jefferson: From the 
Heart-Lung Machine to the ‘Portable’ Total Artificial Heart
John H. Gibbon, Jr., MD, poses with his “Model II” heart-lung machine on the tenth anniversary of the 
world’s first successful extracorporeal cardiac surgery. On May 6, 1953 at Jefferson Medical College 
Hospital, Dr. Gibbon and his staff, closed a very serious septal defect between the upper chambers of 
the heart of eighteen-year-old Cecelia Bavolek. Ms. Bavolek was connected to the device for three-
quarters of an hour and for 26 crucial minutes she totally depended upon the machine’s artificial 
cardiac and respiratory functions. (Images courtesy of Thomas Jefferson University Archives, Scott 
Memorial Library.)
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“The surgical options for treating advanced 
heart failure are continually evolving. In 
addition to the introduction of new devices, 
such as the SynCardia Total Artificial Heart, 
we’re finding new ways to manage patients 
previously thought untreatable.
“For example, Jefferson is joining heart 
centers across the country in learning 
how to better select patients for the Left 
Ventricular Assist Device (LVAD). Historically, 
patients with heart failure had not explored 
surgical treatments until their condition had 
progressed significantly. Thus, most patients 
receiving the LVAD were quite sick.
“Today, we’re discovering that if we can 
catch some patients earlier in the process, we 
can obtain better results. For certain patients, 
the LVAD pump can support a high quality 
of life. In fact, I’ve had patients who have 
traveled abroad with the pump and others 
who have able to get back to work just a few 
months after surgery.” 
John Entwistle, III, MD, PhD 
Surgical Director, Cardiac Transplantation  
and Mechanical Circulatory Support,  
and Associate Professor of Surgery
To learn more visit: 
www.jeffersonhospital.org/cardiothoracic
Continued innovation in 
treating advanced heart failure
The Cardiac Transplantation and 
Mechanical Circulatory Support 
Program, led by director John Entwistle, 
III, MD, PhD, offers several leading-
edge treatment options to patients 
with advanced heart failure. Options 
include the latest-generation left 
ventricular assist devices (LVADs) and 
the SynCardia temporary Total Artificial 
Heart (TAH). 
In 2012, the program acquired the 
SynCardia TAH device, which now 
boasts a mobile software driver (just 
recently approved by the FDA) to 
operate the device outside of a hospital 
setting. This allows some patients 
awaiting a heart transplant to return 
home and, in some cases, resume their 
normal activities. 
Treatment options for end-state heart 
failure are a permanent LVAD, LVAD  
as a bridge to transplant, or a heart 
transplant. But LVAD options are viable 
only for patients with failure of the left  
side of the heart. For those with failure  
of the right side or both sides of the heart, 
and for those with cardiac amyloidosis 
(“stiff heart syndrome”), there has not 
been a good option for returning patients 
home. SynCardia’s portable driver should 
change that, and Jefferson is working to 
identify an optimal candidate for the first 
implant procedure.
“Because of these advanced therapies –  
from the SynCardia TAH device and 
our LVAD capabilities to our unique 
ECMO equipment – Jefferson is able 
to successfully treat a sicker group of 
patients who otherwise would have a 
very poor prognosis,” concludes Dr. 
Diehl. “We are honored to continue  
Dr. Gibbon’s legacy of innovative  
patient care.”
A lecture on May 2nd will highlight  
the anniversary – see page 4.
Surgeon Speaks
Dr. Entwistle demonstrates the orientation  
of a Left Ventricular Assist Device.
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